ライフサイエンスコーパス: rifampicin

1 oral cabotegravir and oral rilpivirine with rifampicin.

2 tions conferring resistance to isoniazid and rifampicin.

3 st maintenance dose when coadministered with rifampicin.

4 rmulations of cabotegravir, rilpivirine, and rifampicin.

5 justed to manage drug-drug interactions with rifampicin.

6 late antimicrobial compounds doxycycline and rifampicin.

7 herapies with 3 to 4 months of isoniazid and rifampicin.

8 monotherapy and in combination therapy with rifampicin.

9 se with resistance to at least isoniazid and rifampicin.

10 one that is resistant to both isoniazid and rifampicin.

11 the former necessitating discontinuation of rifampicin.

12 of Mycobacterium smegmatis to challenge with rifampicin.

13 tude as spontaneous resistance to drugs like rifampicin.

14 plets containing TAG and in its tolerance of rifampicin.

15 tant to host RNA polymerase (RNAP) inhibitor rifampicin.

16 10-fold induction in response to PXR agonist rifampicin.

17 mutation are viable and highly resistant to rifampicin.

18 pregulation of RNA polymerase in response to rifampicin.

19 netic factors that mediate susceptibility to rifampicin.

20 ified rpoB mutation conferring resistance to rifampicin.

21 efficient than an equivalent amount of free rifampicin.

22 lucose media without and with the antibiotic rifampicin.

23 ell growth rates and by prior treatment with rifampicin.

24 utated rpoB gene that provides resistance to rifampicin.

25 e coadministered with 600 mg once-daily oral rifampicin.

26 the efficacy and tolerability of fully oral rifampicin 10 mg/kg plus clarithromycin 15 mg/kg extende

27 Standard antimicrobial treatment with oral rifampicin 10 mg/kg plus intramuscular streptomycin 15 m

28 g, isoniazid, pyrazinamide, and SQ109; 63 to rifampicin 10 mg/kg, isoniazid, pyrazinamide, and moxifl

29 oniazid, pyrazinamide, and ethambutol; 59 to rifampicin 10 mg/kg, isoniazid, pyrazinamide, SQ109; 57

30 9-month antituberculosis regimen (containing rifampicin 10 mg/kg/day) with an intensified regimen wit

31 with an intensified regimen with higher-dose rifampicin (15 mg/kg/day) and levofloxacin (20 mg/kg/day

32 mg/kg, isoniazid, pyrazinamide, SQ109; 57 to rifampicin 20 mg/kg, isoniazid, pyrazinamide, and SQ109;

33 patients to different treatment arms (63 to rifampicin 35 mg/kg, isoniazid, pyrazinamide, and ethamb

34 e hypothesis that the use of higher doses of rifampicin (35 mg/kg) will significantly reduce treatmen

35 zed controlled phase 2 trials comparing oral rifampicin 450 mg (~10 mg/kg) to intensified regimens in

36 ed controlled phase II trials comparing oral rifampicin 450mg (~10mg/kg) to intensified regimens incl

37 r a daily standard control regimen (10 mg/kg rifampicin, 5 mg/kg isoniazid, 25 mg/kg pyrazinamide, an

38 ber of fixed-dose combination tablets [75 mg rifampicin, 50 mg isoniazid, 150 mg pyrazinamide]) and t

39 sation list to receive 2 weeks of adjunctive rifampicin (600 mg or 900 mg per day according to weight

40 ns can grow in bulk-lethal concentrations of rifampicin, a first-line anti-tuberculous antibiotic tar

41 In this work, rifampicin, a first-line antitubercular agent, was encap

42 ered intramuscularly; their interaction with rifampicin, a first-line antituberculosis agent, has not

43 iotic rifampicin (RIF) to 2'-N-hydroxy-4-oxo-rifampicin, a metabolite with much lower antimicrobial a

44 Among these compounds, rifampicin, a well-known antibiotic, showed the stronges

45 Dose escalation of rifampicin achieves >90% Wolbachia depletion in time per

46 The inhibitory effects of rifampicin against amyloid-beta and tau oligomers were e

47 es also showed potency comparable to that of rifampicin against the nonreplicating streptomycin-starv

48 Rifampicin also inhibited cytochrome c release from the

49 participants were randomly assigned: 370 to rifampicin and 388 to placebo.

50 ue 9 and 16 at 4 mug/mL decreased the MIC of rifampicin and clarithromycin against the same pathogens

51 inical and cost-effectiveness of antibiotic (rifampicin and clindamycin) or silver shunts compared wi

52 Multidrug resistance to rifampicin and dapsone was observed in 8 relapses and 4

53 tions that are beneficial in the presence of rifampicin and deleterious in its absence.

54 ck lamA are more uniform and more rapid with rifampicin and drugs that target the cell wall.

55 Both rifampicin and efavirenz are activators of the pregnane

56 acetate (MPA) would increase when given with rifampicin and efavirenz, thus increasing risk of ovulat

57 DMPA, when given with rifampicin and efavirenz, was safe.

58 icin susceptible (INH-R), and susceptible to rifampicin and isoniazid (INH-S + RIF-S).

59 tively, at month 1 (with similar results for rifampicin and isoniazid at month 5).

60 The predicted resistance to rifampicin and isoniazid exceeded 90% sensitivity and sp

61 se-negative findings were caused by uncommon rifampicin and isoniazid resistance mutations.

62 st effective drugs against tuberculosis (ie, rifampicin and isoniazid), which is called multidrug-res

63 d to the two first-line antitubercular drugs rifampicin and isoniazid.

64 ion homogenate were simulated for isoniazid, rifampicin and pyrazinamide and moxifloxacin.

65 s taking a thrice-weekly TB regimen, and low rifampicin and pyrazinamide concentrations were associat

66 lity, we show that the key sterilizing drugs rifampicin and pyrazinamide efficiently penetrate the si

67 id this for isoniazid, kanamycin, ofloxacin, rifampicin, and streptomycin resistance in Mycobacterium

68 Similar activity was exhibited against rifampicin- and isoniazid-resistant M. tuberculosis stra

69 ic-impregnated (0.15% clindamycin and 0.054% rifampicin; antibiotic shunt group), or silver-impregnat

70 Isoniazid and rifampicin are two of the most powerful first-line anti-

71 ost-treatment follow-up: one in the 35 mg/kg rifampicin arm and none in the moxifloxacin arm.

72 a direct demonstration using amiodarone and rifampicin as model drugs, we showed that matured Huh7s

73 In 13-month-old Tg2576 mice, oral rifampicin at 0.5 mg/day for 1 month decreased amyloid-b

74 In the Morris water maze, rifampicin at 1 mg/day improved memory of the mice to a

75 efavirenz-based antiretroviral treatment and rifampicin-based TB treatment.

76 enz-based antiretroviral treatment (ART) and rifampicin-based TB treatment.

77 Participants on rifampicin-based tuberculosis treatment <=8 weeks were r

78 Among adults with HIV receiving rifampicin-based tuberculosis treatment, twice-daily DTG

79 g factors, is affected by amino acids of the Rifampicin-binding pocket, suggesting altered RNA cappin

80 n-allopathic practitioners do not treat with rifampicin, but because of the high rates of inappropria

81 ed resistance to isoniazid, streptomycin and rifampicin by around 1973, indicating continuous circula

82 including drugs with similar (isoniazid and rifampicin (C(MAX) = 400 ng/ml)) and different half-live

83 Functional analysis further revealed that rifampicin can enhance lipid accumulation in human prima

84 at elevated exposures of orally-administered rifampicin can lead to Wolbachia depletions from filaria

85 s to PICC allocation was impractical because rifampicin caused brown staining of the antimicrobial-im

86 combination therapy with three antibiotics: rifampicin, clofazimine, and dapsone.

87 If isoniazid Cmax was <4.6 mg/L and rifampicin Cmax/MIC <28, the isoniazid concentration had

88 tive interactions between isoniazid Cmax and rifampicin Cmax/MIC ratio on 2-month culture conversion.

89 ses using MARS identified isoniazid Cmax and rifampicin Cmax/MIC thresholds below which there is conc

90 was observed in 19%; a 1-mug/mL decrease in rifampicin concentration was independently associated wi

91 The low rifampicin concentrations observed in all compartments l

92 ion size that is able to grow in bulk-lethal rifampicin concentrations via upregulation of basal rpoB

93 Rifampicin concentrations were low in all three compartm

94 Rifampicin concentrations were lower with human immunode

95 Rifampicin concentrations were subtherapeutic in most In

96 t of B. melitensis infected macrophages with rifampicin-containing nanoparticles rapidly eliminated v

97 afety in humans, these results indicate that rifampicin could be a promising, ready-to-use medicine f

98 Rifampicin CSF concentrations were described by a partit

99 Rifampicin CSF concentrations were described by a partit

100 e initially tested five candidate compounds: rifampicin, curcumin, epigallocatechin-3-gallate, myrice

101 In addition, rifampicin decreased the level of p62/sequestosome-1 in

102 Northern blotting experiments with rifampicin disclosed that the regulation of yciF express

103 o approximately 70% upon increasing the oral rifampicin dose from 10 to 30 mg/kg, and predicted that

104 l from ~50% to ~70% upon increasing the oral rifampicin dose from 10 to 30mg/kg, and that higher dose

105 We suggest a rifampicin dose of at least 30 mg/kg to be investigated

106 We suggest a rifampicin dose of at least 30mg/kg to be investigated i

107 ensified antimicrobial treatment with higher rifampicin doses may improve outcome of tuberculous meni

108 ed treatment with the antimycobacterial drug rifampicin enhanced the effect.

109 esistance data across five drugs (isoniazid, rifampicin, ethambutol, pyrazinamide, and streptomycin),

110 Rifampicin even accumulates in necrotic caseum, a critic

111 o compare the average and the variability of rifampicin exposure after weight-band dosing and flat-do

112 Higher rifampicin exposure substantially decreased the risk of

113 ing and only 47% of children would reach the rifampicin exposure target.

114 Rifampicin exposure were simulated using previously publ

115 the best covariate to explain variability of rifampicin exposure.

116 the best covariate to explain variability of rifampicin exposure.

117 was to characterize the relationship between rifampicin exposures and mortality in order to identify

118 As these regimens omit isoniazid, rifampicin, fluoroquinolones and injectable aminoglycosi

119 oparticles demonstrated sustained release of rifampicin for a week with the antimicrobial activity pe

120 particle cocktail containing doxycycline and rifampicin for five days decreased bacterial burden by t

121 n in liquid media was faster in the 35 mg/kg rifampicin group than in the control group (median 48 da

122 erved; however, 63 (17%) participants in the rifampicin group versus 39 (10%) in the placebo group ha

123 cal approaches for analysis of isoniazid and rifampicin has also been presented.

124 rrent evidence suggests that the minocycline-rifampicin-impregnated CVC appears to be the most effect

125 nefit or harm associated with miconazole and rifampicin-impregnated PICCs compared with standard PICC

126 dditional putative compensatory mutations to rifampicin in this dataset.

127 ning TAG and develop phenotypic tolerance to rifampicin in two in vitro models of dormancy including

128 y of antibiotics (doxycycline, oxacillin and rifampicin) in preventing Staphylococcus aureus biofilms

129 BEL repressed rifampicin-induced gene expression of CYP3A4 and multidr

130 BEL decreased rifampicin-induced resistance to SN-38, the active metab

131 International Study of Patients with HIV on Rifampicin ING is a noncomparative, active-control, rand

132 Under cell-free conditions, rifampicin inhibited oligomer formation of amyloid-beta,

133 e most frequent mutation among isoniazid and rifampicin isolates was S315T in katG and S450L in rpoB

134 Among 404 participants, rifampicin, isoniazid, and pyrazinamide concentrations w

135 ected) were intensively sampled to determine rifampicin, isoniazid, and pyrazinamide plasma concentra

136 Antituberculosis therapy (rifampicin, isoniazid, ethambutol and pyrazinamide) was

137 lasma and intrapulmonary pharmacokinetics of rifampicin, isoniazid, pyrazinamide, and ethambutol, and

138 nly regimens (OR, 0.41 [CrI, 0.19 to 0.85]), rifampicin-isoniazid regimens of 3 to 4 months (OR, 0.53

139 to 4 months (OR, 0.53 [CrI, 0.36 to 0.78]), rifampicin-isoniazid-pyrazinamide regimens (OR, 0.35 [Cr

140 loration of body fluids with higher doses of rifampicin it was not possible to mask patients and clin

141 The bactericidal drugs isoniazid and rifampicin kill greater than 99% of exponentially growin

142 e detection of drugs such as doxorubicin and rifampicin (LOD = 18 nM/9.7 ppb and 202 nM/164 ppb, resp

143 Twenty-six percent of patients had Cmax of rifampicin <8 mg/L, pyrazinamide <35 mg/L, and isoniazid

144 Subtherapeutic cutoffs were: rifampicin <8 ug/mL, isoniazid <3 ug/mL, and pyrazinamid

145 (ug/mL) criteria were determined as follows: rifampicin (<=0.125), isoniazid (<=0.25), ethambutol (<=

146 former secretes larger amounts of GGT, and a rifampicin messenger RNA stability study showed that one

147 Rifampicin monooxygenase (RIFMO) catalyzes the N-hydroxy

148 (26.7%) patients, MDR in 15 (4.7%) patients, rifampicin monoresistance in 1 patient (0.3%), and INH-S

149 country level with isoniazid monoresistance, rifampicin monoresistance, multidrug resistance (MDR), f

150 and safety of 6-month isoniazid monotherapy, rifampicin monotherapy, and combination therapies with 3

151 mpicin, or ertapenem followed by combination rifampicin, moxifloxacin, and metronidazole for 6 months

152 K models predicted the theoretical effect of rifampicin on cabotegravir and rilpivirine LA intramuscu

153 ffects of co-administration of efavirenz and rifampicin on the pharmacokinetics of depot medroxyproge

154 A rifampicin-only regimen was associated with the fewest a

155 to 72 months (OR, 0.50 [CrI, 0.41 to 0.62]), rifampicin-only regimens (OR, 0.41 [CrI, 0.19 to 0.85]),

156 hase was linked to L. plantarum tolerance to rifampicin, opposite to a previously identified mode of

157 ither a PICC impregnated with miconazole and rifampicin or a standard (non-antimicrobial-impregnated)

158 , paenipeptins, alone or in combination with rifampicin or clarithromycin, are promising candidates f

159 00% of participants who were pretreated with rifampicin or efavirenz followed by RTV-containing regim

160 tuberculosis prevention regimens containing rifampicin or rifapentine are as effective as longer, is

161 eatment with combinations of clindamycin and rifampicin, or ertapenem followed by combination rifampi

162 atio to receive (all orally) either 35 mg/kg rifampicin per day with 15-20 mg/kg ethambutol, 20 mg/kg

163 n per day with 400 mg moxifloxacin, 20 mg/kg rifampicin per day with 300 mg SQ109, 10 mg/kg rifampici

164 fampicin per day with 300 mg SQ109, 10 mg/kg rifampicin per day with 300 mg SQ109, or a daily standar

165 er day with 15-20 mg/kg ethambutol, 20 mg/kg rifampicin per day with 400 mg moxifloxacin, 20 mg/kg ri

166 y 14 weeks of 5 mg/kg isoniazid and 10 mg/kg rifampicin per day.

167 sgow Coma Scale score, and higher individual rifampicin plasma exposure reducing the hazard.

168 asgow Coma Scale score and higher individual rifampicin plasma exposure reducing the hazard.

169 ed and those with TBI were offered isoniazid-rifampicin preventive therapy for 3 months.

170 other small thiols with either isoniazid or rifampicin prevents the formation of drug-tolerant and d

171 INTERPRETATION: Adjunctive rifampicin provided no overall benefit over standard ant

172 andard tuberculosis therapy (oral isoniazid, rifampicin, pyrazinamide, and ethambutol; HRZE), or pret

173 picin-susceptible TB (Hr-TB), which includes rifampicin, pyrazinamide, ethambutol, and levofloxacin.

174 regimens (OR, 0.35 [CrI, 0.19 to 0.61]), and rifampicin-pyrazinamide regimens (OR, 0.53 [CrI, 0.33 to

175 sceptible pulmonary tuberculosis, isoniazid, rifampicin, PZA, and ethambutol (HRZE regimen).

176 APPOSK mice at 0.5 and 1 mg/day for 1 month, rifampicin reduced the accumulation of amyloid-beta olig

177 ort for ongoing clinical trials of high-dose rifampicin regimens.

178 CA, USA) for Mycobacterium tuberculosis and rifampicin resistance (Xpert) in sputum samples (standar

179 Isoniazid resistance evolved before rifampicin resistance 46 times, whereas rifampicin resis

180 mingly arose before mutations that conferred rifampicin resistance across all of the lineages, geogra

181 lecular diagnostics that include markers for rifampicin resistance alone will be insufficient to iden

182 detection of smear-negative tuberculosis and rifampicin resistance and to estimate and compare Xpert

183 y testing are that (i) its ability to detect rifampicin resistance can lead to long-term cost savings

184 tant mutations even outside the well-defined rifampicin resistance determining region (RRDR), using c

185 fore rifampicin resistance 46 times, whereas rifampicin resistance evolved prior to isoniazid only tw

186 s targets to detect the mycobacteria and the rifampicin resistance from gDNA directly extracted from

187 B patients was higher than the prevalence of rifampicin resistance globally.

188 Secondary outcomes relating to infection, rifampicin resistance in positive blood or CSF cultures,

189 ere similar between the two groups, although rifampicin resistance in positive cultures of PICC tips

190 ated the incidence of acquired isoniazid and rifampicin resistance in rifampicin-susceptible tubercul

191 Rifampicin resistance in Xpert-positive patients was inf

192 Rifampicin resistance is a major therapeutic challenge,

193 The global prevalence of rifampicin resistance is well documented, occurring in 3

194 tivities and specificities for isoniazid and rifampicin resistance of the tools were high, whereas th

195 f the mutations revealed that acquisition of rifampicin resistance often preceded isoniazid in our is

196 Patients without evidence of rifampicin resistance on phenotypic test who took at lea

197 ed these insights to develop a computational rifampicin resistance predictor capable of identifying r

198 he sensitivity of Xpert MTB/RIF in detecting rifampicin resistance to 93.8%.

199 pooled sensitivity and specificity to detect rifampicin resistance was 86% (95% credible interval 53-

200 Rifampicin resistance was detected for the first time in

201 Rifampicin resistance was detected in 3 eyes by rpoB gen

202 Rifampicin resistance was identified in 7.8% of the succ

203 seminated tuberculosis, sepsis syndrome, and rifampicin resistance were associated with mortality.

204 t also higher accuracy, while also detecting rifampicin resistance).

205 rst-line anti-TB therapy risks selecting for rifampicin resistance, and hence MDR-TB.

206 s improved the detection of tuberculosis and rifampicin resistance, but its sensitivity is inadequate

207 resistance was significantly associated with rifampicin resistance, this drug may still be effective

208 of Western Province in PNG, and investigates rifampicin resistance-associated mutations.

209 SCV that arose spontaneously while studying rifampicin resistance.

210 t of Xpert for detection of tuberculosis and rifampicin resistance.

211 a and Xpert performed similarly in detecting rifampicin resistance.

212 tra and Xpert specificities for detection of rifampicin resistance.

213 ed MDR strains had compensatory mutations of rifampicin resistance.

214 antiretroviral therapy was 10%, with limited rifampicin resistance.

215 ents and in settings with high prevalence of rifampicin resistance.

216 alent, but it allowed for rapid detection of rifampicin resistance.

217 resistance was significantly associated with rifampicin resistance.

218 carried a rare rpoB mutation associated with rifampicin resistance.

219 detection of Mycobacterium tuberculosis and rifampicin resistance.

220 cs employed in South Africa that assess only rifampicin resistance.

221 ected to rpoB gene sequencing to demonstrate rifampicin resistance.

222 risk group were only included in analyses of rifampicin-resistance detection.

223 is applied for the detection of a common Mtb rifampicin-resistance mutation, rpoB 531 (TCG/TTG).

224 Losses were substantially higher among rifampicin- resistant cases, with only 22% successfully

225 various novel rifampicin-susceptible (RS) or rifampicin-resistant (RR) TB regimens that differed on s

226 The prevalence and predictors of Rifampicin-resistant (RR) TB, a proxy for MDR-TB, and th

227 hift mutations have been reported in rpoB in rifampicin-resistant clinical isolates of Mycobacterium

228 against metronidazole-, clarithromycin-, and rifampicin-resistant Hp clinical isolates.

229 recruited patients with drug-susceptible or rifampicin-resistant pulmonary tuberculosis from seven s

230 -resistant Mycobacterium leprae, including a rifampicin-resistant strain, is reported.

231 ng pocket, suggesting altered RNA capping in Rifampicin-resistant strains.

232 However, GeneXpert identified rifampicin-resistant TB in one patient, who was initiall

233 s versus 28.9% of survivors, p < 0.001), and rifampicin-resistant tuberculosis (16.9% of deaths versu

234 cross-sectional study of HHCs of MDR-TB and rifampicin-resistant tuberculosis (RR-TB) index cases fr

235 South Africa has a large burden of rifampicin-resistant tuberculosis (RR-TB), with 18,734 p

236 ating the shorter 9 to 12 months regimen for rifampicin-resistant tuberculosis (RR-TB).

237 Xpert MTB/RIF (Xpert) detects rifampicin-resistant tuberculosis (RR-tuberculosis), ena

238 uberculosis died and four (7%) patients with rifampicin-resistant tuberculosis died.

239 Patients with rifampicin-resistant tuberculosis received 56 days of th

240 to distinguish between drug-susceptible and rifampicin-resistant tuberculosis.

241 and disease, including HIV co-infection and rifampicin-resistant tuberculosis.

242 deficiency virus (HIV)-coinfected cases) and rifampicin-resistant tuberculosis.

243 till be effective in 19-63% of patients with rifampicin-resistant tuberculosis.

244 00)PaZ, and 61 to HRZE) and 60 patients with rifampicin-resistant tuberculosis.

245 cases of TB are multidrug-resistant (MDR) or rifampicin-resistant.

246 enes, conferring resistance to isoniazid and rifampicin respectively.

247 Thus, rifampicin response is complex and due to a combination

248 st optimized the size, surface modification [rifampicin (RF) conjugation], and concentration (2.5 nM)

249 several TB drugs, including front line drugs rifampicin (RIF) and rifabutin (RFB), resulting in alter

250 ection and highly sensitive determination of rifampicin (RIF) by square wave adsorptive stripping vol

251 Rifampicin (Rif) is a first-line therapeutic used to tre

252 roxylation of the natural product antibiotic rifampicin (RIF) to 2'-N-hydroxy-4-oxo-rifampicin, a met

253 Wolbachia but synergized with minocycline or rifampicin (RIF) to deplete symbionts, block embryogenes

254 We have developed a tissue model for rifampicin (RIF), an antibiotic used to treat tuberculos

255 sence of the antibiotics isoniazid (INH) and rifampicin (RIF), in an attempt to develop the assay as

256 ugs [i.e. isoniazid (INH), ethambutol (EMB), rifampicin (RIF), pyrazinamide (PZA)], multi-drug resist

257 equire TB treatment with isoniazid (INH) and rifampicin (RIF), which affect cytochrome P450 and antir

258 gnificant decreases were shown by miconazole-rifampicin (RR, 0.14 [95% CI, .05-.36]), 5-fluorouracil

259 SI reduction was associated with minocycline-rifampicin (RR, 0.29 [95% CI, .16-.52]) and silver (RR,

260 ct tracing and administration of single-dose rifampicin (SDR) into routine leprosy control activities

261 Patients with newly diagnosed, rifampicin-sensitive, previously untreated pulmonary tub

262 Baicalein, curcumin, and rifampicin showed concentration-dependent inhibition of

263 Treatment with rifampicin shows that active transcription is necessary

264 n of urinary catheters with a combination of rifampicin, sparfloxacin and triclosan.

265 are essential antituberculosis drugs in new rifampicin-sparing regimens.

266 s and deep sequencing (Tnseq) to investigate rifampicin-specific phenotypic resistance using two diff

267 stranslation rates, which result in enhanced rifampicin-specific phenotypic resistance.

268 Discordant rifampicin susceptibility results of Xpert MTB/RIF and m

269 ctively identify subpopulations with altered rifampicin susceptibility.

270 tidrug resistant (MDR), isoniazid resistant, rifampicin susceptible (INH-R), and susceptible to rifam

271 We modeled the introduction of various novel rifampicin-susceptible (RS) or rifampicin-resistant (RR)

272 regimen for people with isoniazid-resistant, rifampicin-susceptible TB (Hr-TB), which includes rifamp

273 uired isoniazid and rifampicin resistance in rifampicin-susceptible tuberculosis in a setting of high

274 GeneXpert MTB/RIF-confirmed patients with rifampicin-susceptible tuberculosis were recruited at an

275 proposed dosing approach improved estimated rifampicin target exposure attainment to 62% and equalis

276 d by current diagnostic algorithms driven by rifampicin testing, highlighting the need for new rapid

277 With rifampicin, the difference was 11 fewer incident tubercu

278 designs for electroanalysis of isoniazid and rifampicin, the most important medicines for patients wi

279 5 to 8) for 18 to 34-year-olds treated with rifampicin to 63 (50 to 74) for people older than 64 yea

280 ges and subsequent bacterial release enabled rifampicin to effectively kill Mtb at concentrations tha

281 tion-associated elongation factor, increased rifampicin tolerance in all experimental conditions.

282 ies multiple genetic factors associated with rifampicin tolerance in mycobacteria, and may allow corr

283 tance using two different in vitro models of rifampicin tolerance in Mycobacterium smegmatis.

284 ux pump that is linked to macrophage-induced rifampicin tolerance.

285 in BBD-treated mice were lower than those in rifampicin-treated mice.

286 Rifampicin treatment to 14-15-month-old tau609 mice at 0

287 d CYP2C19 inductions were achieved following rifampicin treatment.

288 ) between these LA antiretroviral agents and rifampicin using physiologically based pharmacokinetic (

289 ek 12, 62 (17%) of participants who received rifampicin versus 71 (18%) who received placebo experien

290 oad inhibition of plastid transcription with rifampicin was also able to suppress cell death in fc2 m

291 Induction potential of rifampicin was also qualified by comparing the DDI betwe

292 Single resistance to rifampicin was detected in 1 new case.

293 INTERPRETATION: A dose of 35 mg/kg rifampicin was safe, reduced the time to culture convers

294 A dose of 35 mg/kg rifampicin was safe, reduced the time to culture convers

295 and absence of the RNA polymerase inhibitor rifampicin, we identify hundreds of nascent transcripts

296 that clinically relevant dose elevations of rifampicin, which have recently been determined as safe

297 Rifampicin, which inhibits bacterial RNA polymerase, pro

298 tions, it is likely that coadministration of rifampicin with these LA formulations will result in sub

299 cated for ultra-trace level determination of rifampicin with very low detection limit (4.55x10(-17)M)

300 We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed trea